Haoyan (michael) Zhou PhD, MS

Dr. Haoyan (Michael) Zhou is Director of Non-Viral Delivery at Eli Lilly, where he leads efforts to advance next-generation nucleic acid and oligonucleotide therapies. With over a decade of experience spanning Lilly, Spark Therapeutics, GSK, and Frontage Laboratories, he has built deep expertise in formulation development, biocatalysis, and late-stage gene therapy drug product design. Dr. Zhou earned his PhD in Biomedical Engineering from Case Western Reserve University and brings a strong track record of scientific leadership and innovation to accelerating the development of transformative medicines.